1
Home
Companies

PolyPeptide Group

#5828

Rank

$1.15B

Marketcap

CH Switzerland

Country

PolyPeptide Group
Leadership team

Dr. Raymond De Vre Ph.D. (Chief Exec. Officer)

Mr. Jan Fuhr Miller (Chief Financial Officer)

Mr. Jens Fricke (Director of Global Operations)

Products/ Services
Manufacturing
Number of Employees
1,000 - 20,000
Headquarters
Limhamn, Skane Lan, Sweden
Established
1996
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
PPGN.SW
Social Media
URL
https://www.polypeptide.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
History

PolyPeptide was founded in 1979 as a contract manufacturer of synthetically produced peptides for the pharmaceutical industry. Through innovation, expansion, and investments in its proprietary technologies, PolyPeptide has evolved into a leading provider of high-quality peptides, biobetters, and biosimilars for its global customers.

Mission
Our mission is to be the global leader in the development and manufacturing of peptides, active pharmaceutical ingredients, and biobetters that are used to improve patients' quality of life.
Vision
Our vision is to be the world's trusted partner in bringing innovative peptide solutions to the global healthcare market.
Key Team

Mr. Michael Staheli (Head of Investor Relations & Corp. Communications)

Ms. Christina Del Vecchio (Gen. Counsel & Corp. Sec.)

Mr. Neil James Thompson (Director of Global Sales & Marketing)

Monika Casanova (Chief HR Officer)

Mr. Jan Christensen (Exec. Officer)

Recognition and Awards
With over 40 years at the forefront of peptide innovation and leadership, PolyPeptide Group has been recognized with several awards, including BioPharma Excellence Award, Overall Supplier of the Year Award, International Supplier Award, and the Award of Excellence in Peptide Manufacturing.
References

https://in.investing.com/equities/polypeptide-group-ag

https://finance.yahoo.com/quote/PPGN.SW/profile?p=PPGN.SW

https://www.crunchbase.com/organization/polypeptide-group

https://companiesmarketcap.com/

https://www.polypeptide.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

PolyPeptide Group
Leadership team

Dr. Raymond De Vre Ph.D. (Chief Exec. Officer)

Mr. Jan Fuhr Miller (Chief Financial Officer)

Mr. Jens Fricke (Director of Global Operations)

Products/ Services
Manufacturing
Number of Employees
1,000 - 20,000
Headquarters
Limhamn, Skane Lan, Sweden
Established
1996
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
PPGN.SW
Social Media
URL
https://www.polypeptide.com